Gain Therapeutics (GANX) Price to Sales (2021 - 2023)

Gain Therapeutics has reported Price to Sales for 3 years, with the latest figure at 1055.82 in Q1 2023.

• On a quarterly basis, Price to Sales fell 2.23% year-over-year to 1055.82 in Q1 2023; TTM through Dec 2023 was 769.88, a 190.0% increase from a year earlier, with the FY2023 full-year figure at 769.88, up 190.0% from the prior year.
• Price to Sales was 1055.82 for Q1 2023 at Gain Therapeutics, up from 449.83 in the prior quarter.
• The five-year high for Price to Sales was 30186.15 in Q1 2021, with the low at 449.83 in Q2 2022.
• Average Price to Sales over 3 years is 5547.34, with a median of 1331.84 recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Price to Sales sank 96.42% in 2022, then decreased 2.23% in 2023.
• Over 3 years, Price to Sales stood at 1493.4 in 2021, then tumbled by 69.88% to 449.83 in 2022, then jumped by 134.71% to 1055.82 in 2023.
• The last three Price to Sales figures came in at 1055.82 (Q1 2023), 449.83 (Q2 2022), and 1079.92 (Q1 2022), per Business Quant data.